AAPL352.41+0.50 (+0.14%) ▲|ABBV285.26-7.57 (-2.58%) ▼|ABT105.01+0.30 (+0.29%) ▲|ACN229.79-9.50 (-3.97%) ▼|ADBE227.33-8.23 (-3.49%) ▼|AMAT350.42+1.19 (+0.34%) ▲|AMD521.56+18.15 (+3.61%) ▲|AMGN444.81-13.12 (-2.87%) ▼|AMT185.48+2.30 (+1.26%) ▲|AMZN266.14+8.25 (+3.20%) ▲|AVGO354.80+13.20 (+3.86%) ▲|AXP315.34-0.44 (-0.14%) ▼|BA163.04-0.88 (-0.53%) ▼|BAC48.87-0.57 (-1.15%) ▼|BKNG153.49-0.97 (-0.63%) ▼|BLK1,175.71-4.96 (-0.42%) ▼|BMY60.03-1.32 (-2.15%) ▼|BNY148.47-1.32 (-0.88%) ▼|BRK-B574.32-12.44 (-2.12%) ▼|C117.68-2.26 (-1.88%) ▼|CAT558.37-12.42 (-2.18%) ▼|CL98.99-0.63 (-0.63%) ▼|CMCSA25.34+0.03 (+0.13%) ▲|COF184.29-2.49 (-1.33%) ▼|COP134.94-4.54 (-3.25%) ▼|COST1,103.82-6.26 (-0.56%) ▼|CRM189.64-4.88 (-2.51%) ▼|CSCO96.40+1.29 (+1.36%) ▲|CVS81.63-4.19 (-4.88%) ▼|CVX206.32-8.04 (-3.75%) ▼|DE646.41-2.82 (-0.43%) ▼|DHR228.52+2.75 (+1.22%) ▲|DIS123.08+6.14 (+5.25%) ▲|DUK130.32+0.48 (+0.37%) ▲|EMR162.15+3.00 (+1.89%) ▲|FDX318.25-1.69 (-0.53%) ▼|GD350.16-5.47 (-1.54%) ▼|GE328.02+1.62 (+0.50%) ▲|GEV773.03-6.88 (-0.88%) ▼|GILD169.49-0.77 (-0.45%) ▼|GM82.32-1.74 (-2.06%) ▼|GOOG280.82+3.22 (+1.16%) ▲|GOOGL283.55+3.35 (+1.20%) ▲|GS872.39-5.13 (-0.58%) ▼|HD338.95-0.06 (-0.02%) ▼|HON223.64+4.68 (+2.14%) ▲|IBM228.94-2.15 (-0.93%) ▼|INTC54.21-0.96 (-1.74%) ▼|INTU313.92-6.87 (-2.14%) ▼|ISRG424.57-5.97 (-1.39%) ▼|JNJ273.89-4.81 (-1.73%) ▼|JPM324.76-5.21 (-1.58%) ▼|KO98.15-0.65 (-0.65%) ▼|LIN511.59-3.52 (-0.68%) ▼|LLY1,387.50-28.05 (-1.98%) ▼|LMT578.89-11.45 (-1.94%) ▼|LOW221.94+1.48 (+0.67%) ▲|LRCX209.92-0.77 (-0.37%) ▼|MA644.08-1.65 (-0.26%) ▼|MCD274.06-1.77 (-0.64%) ▼|MDLZ66.76+0.01 (+0.02%) ▲|MDT101.08-1.24 (-1.21%) ▼|META614.60-4.27 (-0.69%) ▼|MMM181.32+0.44 (+0.24%) ▲|MO76.53-0.94 (-1.21%) ▼|MRK138.35-5.02 (-3.50%) ▼|MS180.88-2.65 (-1.44%) ▼|MSFT506.69+0.45 (+0.09%) ▲|MU697.30-15.13 (-2.12%) ▼|NEE84.79+0.37 (+0.43%) ▲|NFLX59.77+0.09 (+0.14%) ▲|NKE36.38+0.53 (+1.48%) ▲|NOW90.65-2.25 (-2.42%) ▼|NVDA150.83-4.63 (-2.98%) ▼|ORCL114.33-0.67 (-0.58%) ▼|PEP141.89-0.13 (-0.09%) ▼|PFE28.13-0.34 (-1.19%) ▼|PG170.66-1.07 (-0.62%) ▼|PLTR156.26-0.31 (-0.19%) ▼|PM193.21-1.17 (-0.60%) ▼|QCOM159.09-7.58 (-4.55%) ▼|RTX197.51-0.49 (-0.25%) ▼|SBUX109.15+1.66 (+1.54%) ▲|SCHW92.40+0.56 (+0.61%) ▲|SO94.52+0.92 (+0.98%) ▲|SPG231.84+1.60 (+0.69%) ▲|T22.01-0.28 (-1.27%) ▼|TMO691.98+5.19 (+0.76%) ▲|TMUS163.36-4.54 (-2.70%) ▼|TSLA382.86+2.75 (+0.72%) ▲|TXN290.67-5.20 (-1.76%) ▼|UBER69.15+0.34 (+0.49%) ▲|UNH347.60-42.08 (-10.80%) ▼|UNP301.61+4.58 (+1.54%) ▲|UPS111.30+0.99 (+0.90%) ▲|USB58.38-0.81 (-1.36%) ▼|V415.48-1.29 (-0.31%) ▼|VZ45.99+0.06 (+0.12%) ▲|WFC81.17-1.52 (-1.84%) ▼|WMT127.13-0.39 (-0.31%) ▼|XOM160.95-6.26 (-3.74%) ▼|AAPL352.41+0.50 (+0.14%) ▲|ABBV285.26-7.57 (-2.58%) ▼|ABT105.01+0.30 (+0.29%) ▲|ACN229.79-9.50 (-3.97%) ▼|ADBE227.33-8.23 (-3.49%) ▼|AMAT350.42+1.19 (+0.34%) ▲|AMD521.56+18.15 (+3.61%) ▲|AMGN444.81-13.12 (-2.87%) ▼|AMT185.48+2.30 (+1.26%) ▲|AMZN266.14+8.25 (+3.20%) ▲|AVGO354.80+13.20 (+3.86%) ▲|AXP315.34-0.44 (-0.14%) ▼|BA163.04-0.88 (-0.53%) ▼|BAC48.87-0.57 (-1.15%) ▼|BKNG153.49-0.97 (-0.63%) ▼|BLK1,175.71-4.96 (-0.42%) ▼|BMY60.03-1.32 (-2.15%) ▼|BNY148.47-1.32 (-0.88%) ▼|BRK-B574.32-12.44 (-2.12%) ▼|C117.68-2.26 (-1.88%) ▼|CAT558.37-12.42 (-2.18%) ▼|CL98.99-0.63 (-0.63%) ▼|CMCSA25.34+0.03 (+0.13%) ▲|COF184.29-2.49 (-1.33%) ▼|COP134.94-4.54 (-3.25%) ▼|COST1,103.82-6.26 (-0.56%) ▼|CRM189.64-4.88 (-2.51%) ▼|CSCO96.40+1.29 (+1.36%) ▲|CVS81.63-4.19 (-4.88%) ▼|CVX206.32-8.04 (-3.75%) ▼|DE646.41-2.82 (-0.43%) ▼|DHR228.52+2.75 (+1.22%) ▲|DIS123.08+6.14 (+5.25%) ▲|DUK130.32+0.48 (+0.37%) ▲|EMR162.15+3.00 (+1.89%) ▲|FDX318.25-1.69 (-0.53%) ▼|GD350.16-5.47 (-1.54%) ▼|GE328.02+1.62 (+0.50%) ▲|GEV773.03-6.88 (-0.88%) ▼|GILD169.49-0.77 (-0.45%) ▼|GM82.32-1.74 (-2.06%) ▼|GOOG280.82+3.22 (+1.16%) ▲|GOOGL283.55+3.35 (+1.20%) ▲|GS872.39-5.13 (-0.58%) ▼|HD338.95-0.06 (-0.02%) ▼|HON223.64+4.68 (+2.14%) ▲|IBM228.94-2.15 (-0.93%) ▼|INTC54.21-0.96 (-1.74%) ▼|INTU313.92-6.87 (-2.14%) ▼|ISRG424.57-5.97 (-1.39%) ▼|JNJ273.89-4.81 (-1.73%) ▼|JPM324.76-5.21 (-1.58%) ▼|KO98.15-0.65 (-0.65%) ▼|LIN511.59-3.52 (-0.68%) ▼|LLY1,387.50-28.05 (-1.98%) ▼|LMT578.89-11.45 (-1.94%) ▼|LOW221.94+1.48 (+0.67%) ▲|LRCX209.92-0.77 (-0.37%) ▼|MA644.08-1.65 (-0.26%) ▼|MCD274.06-1.77 (-0.64%) ▼|MDLZ66.76+0.01 (+0.02%) ▲|MDT101.08-1.24 (-1.21%) ▼|META614.60-4.27 (-0.69%) ▼|MMM181.32+0.44 (+0.24%) ▲|MO76.53-0.94 (-1.21%) ▼|MRK138.35-5.02 (-3.50%) ▼|MS180.88-2.65 (-1.44%) ▼|MSFT506.69+0.45 (+0.09%) ▲|MU697.30-15.13 (-2.12%) ▼|NEE84.79+0.37 (+0.43%) ▲|NFLX59.77+0.09 (+0.14%) ▲|NKE36.38+0.53 (+1.48%) ▲|NOW90.65-2.25 (-2.42%) ▼|NVDA150.83-4.63 (-2.98%) ▼|ORCL114.33-0.67 (-0.58%) ▼|PEP141.89-0.13 (-0.09%) ▼|PFE28.13-0.34 (-1.19%) ▼|PG170.66-1.07 (-0.62%) ▼|PLTR156.26-0.31 (-0.19%) ▼|PM193.21-1.17 (-0.60%) ▼|QCOM159.09-7.58 (-4.55%) ▼|RTX197.51-0.49 (-0.25%) ▼|SBUX109.15+1.66 (+1.54%) ▲|SCHW92.40+0.56 (+0.61%) ▲|SO94.52+0.92 (+0.98%) ▲|SPG231.84+1.60 (+0.69%) ▲|T22.01-0.28 (-1.27%) ▼|TMO691.98+5.19 (+0.76%) ▲|TMUS163.36-4.54 (-2.70%) ▼|TSLA382.86+2.75 (+0.72%) ▲|TXN290.67-5.20 (-1.76%) ▼|UBER69.15+0.34 (+0.49%) ▲|UNH347.60-42.08 (-10.80%) ▼|UNP301.61+4.58 (+1.54%) ▲|UPS111.30+0.99 (+0.90%) ▲|USB58.38-0.81 (-1.36%) ▼|V415.48-1.29 (-0.31%) ▼|VZ45.99+0.06 (+0.12%) ▲|WFC81.17-1.52 (-1.84%) ▼|WMT127.13-0.39 (-0.31%) ▼|XOM160.95-6.26 (-3.74%) ▼|
17.4 C
New York
Wednesday, November 18, 2026

Tag: source

Argo Corporation Announces Closing of Strategic Investment

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Argo Corporation (TSXV: ARGH), (OTCQX: ARGHF) (“Argo” or the “Company”), a leader in next-generation transit solutions, announces that it has closed a non-brokered private placement with a strategic investor whose business is related to the manufacturing of potential future vehicle hardware.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WGS

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

ELWT Investor News: If You Have Suffered Losses in Elauwit Connection, Inc. (NASDAQ: ELWT), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Elauwit Connection, Inc. (NASDAQ: ELWT) resulting from allegations that Elauwit may have issued materially misleading business information to the investing public.

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

All-Round for Work & Play: KTC Dual-Mode Monitor H27P6 Adapts to Full-Scenario Needs

All-Round for Work & Play: KTC Dual-Mode Monitor H27P6 Adapts to Full-Scenario Needs

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. (WGS)

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased or otherwise acquired GeneDx Holdings Corp. (“WGS” or the “Company”) (NASDAQ: WGS) securities between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).

LCID SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Lucid Group, Inc. Investors – Contact Kirby McInerney LLP by July 28, 2026

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors it Has Filed a Complaint to Recover Losses Suffered by Purchasers of Verra Mobility Corporation Common...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Publish

DentaQuest Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information

Edelson Lechtzin LLP is investigating data privacy claims arising from the DentaQuest data breach.

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSource